Pfizer (NYSE: PFE) CEO awarded 24 phantom stock units in deferred plan
Rhea-AI Filing Summary
BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on July 15, 2026, at a reported transaction price of $24.82 per unit. Each unit represents one phantom share of common stock under Pfizer's Nonfunded Deferred Compensation and Supplemental Savings Plan.
The phantom units are settled in cash after Bourla's separation from service and may be transferred into an alternative investment account at any time. Following this grant, he holds 772,901 phantom stock units directly under the plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
BOURLA ALBERT
Role
Chairman & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units SSP F1, F2 | 24 | $24.82 | $595.68 |
Holdings After Transaction:
Phantom Stock Units SSP — 772,901 shares (Direct)
Footnotes (2)
- F1. Each unit represents one phantom share of common stock.
- F2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Key Figures
Phantom stock units granted: 24 units
Transaction price per unit: $24.82
Total phantom units after grant: 772,901 units
3 metrics
Phantom stock units granted
24 units
Phantom Stock Units SSP granted to Albert Bourla on July 15, 2026
Transaction price per unit
$24.82
Reported transaction price per Phantom Stock Unit SSP
Total phantom units after grant
772,901 units
Total Phantom Stock Units SSP held directly after the reported grant
Key Terms
Phantom Stock Units SSP, Nonfunded Deferred Compensation and Supplemental Savings Plan, separation from service
3 terms
Phantom Stock Units SSP financial
"Security title reported as "Phantom Stock Units SSP" representing phantom shares"
Nonfunded Deferred Compensation and Supplemental Savings Plan financial
"Acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan"
separation from service financial
"Units are settled in cash following the reporting person's separation from service"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Pfizer (PFE) report for Albert Bourla?
Pfizer reported that Chairman & CEO Albert Bourla received a grant of 24 Phantom Stock Units SSP on July 15, 2026, at a reported price of $24.82 per unit. These are cash-settled phantom units tied to Pfizer common stock.
What are Phantom Stock Units SSP in Pfizer (PFE)'s Form 4?
Phantom Stock Units SSP are awards where each unit represents one phantom share of Pfizer common stock. They are issued under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and are ultimately settled in cash, not in actual shares.
How many phantom stock units does Albert Bourla hold after this Pfizer (PFE) grant?
After this grant, Albert Bourla holds 772,901 Phantom Stock Units SSP directly under Pfizer’s deferred compensation plan. The reported 24-unit award modestly increases his existing phantom stock balance within that plan structure.
How and when are Pfizer (PFE) phantom stock units for Albert Bourla settled?
The phantom stock units are settled in cash following Albert Bourla’s separation from service. Under the plan, these units track Pfizer’s common stock value but are paid out in cash rather than stock when his service ends.
Can Albert Bourla reallocate his Pfizer (PFE) phantom stock units?
Yes. The filing states that these phantom stock units may be transferred into an alternative investment account at any time. This allows Bourla to shift value within Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan.
Does this Pfizer (PFE) Form 4 show Albert Bourla buying or selling common stock?
No. The Form 4 reports a grant of cash-settled phantom stock units, not an open-market purchase or sale of Pfizer common shares. The units represent phantom shares and are paid in cash under the deferred compensation plan.